Conference Coverage

VIDEO: Proposed Alzheimer’s funding boost could mean wider research scope


 

AT AAIC 2016

References

TORONTO – In 2011, President Barack Obama signed into law the National Alzheimer’s Project Act, with the lofty goal of preventing or effectively treating Alzheimer’s disease by 2025. A year later, a panel of leading researchers translated that goal into harsh reality: Reaching it would cost at least $2 billion each year. That level of funding would put Alzheimer’s research on the same footing as research on cancer, heart disease, and HIV – areas that have experienced rapid and sustained clinical progress.

But securing federal funding support has been a slow go. At the end of 2016, even with historic funding increases, the total allocation still fell short of $1 billion. That’s about to change for the better. The proposed 2017 budget, if approved, will boost the allocation to $1.4 billion.

What will that new money mean to researchers who’ve struggled for years to get grants? And what could it mean to doctors, patients, and families who still face a devastating disease with no cure, no prevention, and no effective treatments? Robert J. Egge, chief public policy officer for the Alzheimer’s Association, breaks it down in this video interview at the Alzheimer’s Association International Conference 2016.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Recommended Reading

Recurrent DKA episodes found to trigger cognitive changes
MDedge Family Medicine
Insomnia is pervasive in adult neurodevelopmental disorders
MDedge Family Medicine
Sleep apnea in later life more than doubles subsequent Alzheimer’s risk
MDedge Family Medicine
Long-term metformin use protective against neurodegenerative disease
MDedge Family Medicine
Use simple algorithms to manage dementia
MDedge Family Medicine
Start time for estrogen conveys no cognitive impact
MDedge Family Medicine
Withdrawing risperidone spikes risk for psychotic relapse in hallucinating Alzheimer’s patients
MDedge Family Medicine
VIDEO: Loss of function in Rab10 gene cuts Alzheimer’s risk by up to 40%
MDedge Family Medicine
VIDEO: Medicare pays billions for potentially avoidable hospital admissions in dementia patients
MDedge Family Medicine
Medicare annual wellness visit remains underused
MDedge Family Medicine

Related Articles